R2CHADS2 Score: An Effective Risk Stratification Tool for Contrast-Induced Nephropathy and Cardiovascular Outcomes in...

Area of Science:

• Cardiology
• Nephrology
• Interventional Cardiology

Background:

• Contrast-induced nephropathy (CIN) is a significant complication post-percutaneous coronary intervention (PCI).
• The R2CHADS2 score, initially for thromboembolic risk, is now explored for predicting CIN and MACE.
• ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI (pPCI) are a vulnerable population.

Purpose of the Study:

• To assess the R2CHADS2 score's predictive capability for CIN in STEMI patients undergoing pPCI.
• To evaluate the R2CHADS2 score's utility in predicting long-term MACE in this patient cohort.

Main Methods:

• Retrospective analysis of 1204 STEMI patients undergoing pPCI.
• Categorization of patients into low, moderate, and high-risk groups based on R2CHADS2 scores.
• Comparison of CIN incidence and MACE rates across the risk groups.

Main Results:

• CIN incidence was substantially higher in the high-risk R2CHADS2 group (37.1%) compared to moderate (13.6%) and low-risk (5.5%) groups.
• Hemodialysis was more frequently required in the high-risk group (14.3%).
• MACE rates were significantly elevated in the high-risk group (49.3%) versus moderate (22.1%) and low-risk (12.9%) groups.

Conclusions:

• The R2CHADS2 score demonstrates significant predictive value for CIN in STEMI patients undergoing pPCI.
• The R2CHADS2 score is also a reliable predictor of adverse cardiovascular outcomes, including MACE, in this population.
• Risk stratification using the R2CHADS2 score can aid in identifying high-risk STEMI patients for closer monitoring and potential intervention.